NASDAQ:GNMX - Aevi Genomic Medicine Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.17
+0.30 (1.20%)
Get New Aevi Genomic Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNMX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNMX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aevi Genomic Medicine in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.17.
N/A
The current consensus among 0 investment analysts is to n/a stock in Aevi Genomic Medicine. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
9/28/2017Jefferies Financial GroupReiterated RatingHold$1.50Low
i
8/16/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$9.00 ➝ $7.00Medium
i
8/7/2017Jefferies Financial GroupReiterated RatingHold$1.50Low
i
Rating by Matthew Andrews at Jefferies Financial Group Inc.
5/12/2017Jefferies Financial GroupReiterated RatingHold$1.50Medium
i
Rating by Matthew Andrews at Jefferies Financial Group Inc.
5/10/2017UBS GroupReiterated RatingPositiveN/A
i
3/21/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $9.00High
i
3/21/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $2.50High
i
12/6/2016HC WainwrightInitiated CoverageBuy$14.00N/A
i
Rating by C. Werther at HC Wainwright
11/4/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Michael King at JMP Securities
9/23/2016Jefferies Financial GroupInitiated CoverageBuyN/A
i
6/8/2016JMP SecuritiesReiterated RatingBuy$13.00N/A
i
6/7/2016Needham & Company LLCReiterated RatingBuy$12.00N/A
i
Rating by Chad Messer at Needham & Company LLC
(Data available from 4/18/2016 forward)
Aevi Genomic Medicine logo
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Read More

Today's Range

Now: $0.17
$0.15
$0.18

50 Day Range

MA: $0.17
$0.17
$0.19

52 Week Range

Now: $0.17
$0.11
$0.35

Volume

2,945,816 shs

Average Volume

3,164,141 shs

Market Capitalization

$12.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Aevi Genomic Medicine?

The following Wall Street research analysts have issued reports on Aevi Genomic Medicine in the last year:
View the latest analyst ratings for GNMX.

What is the current price target for Aevi Genomic Medicine?

0 Wall Street analysts have set twelve-month price targets for Aevi Genomic Medicine in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aevi Genomic Medicine in the next year.
View the latest price targets for GNMX.

What is the current consensus analyst rating for Aevi Genomic Medicine?

Aevi Genomic Medicine currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GNMX.

What other companies compete with Aevi Genomic Medicine?

How do I contact Aevi Genomic Medicine's investor relations team?

Aevi Genomic Medicine's physical mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company's listed phone number is 610-254-4201 and its investor relations email address is [email protected] The official website for Aevi Genomic Medicine is www.aevigenomics.com.